Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe

This prospective, observational study examined the real-world use of carfilzomib across 11 European countries in adults with relapsed/refractory multiple myeloma (RRMM) who received at least one prior line of therapy. Carfilzomib and dexamethasone (Kd) use, effectiveness and safety were analyzed. In...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Renato Zambello, Xavier Leleu, Thomas Kuehr, Sorina N. Badelita, Eirini Katodritou, Alessandra Brescianini, Tony Liang, Sally Wetten, Jo Caers
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Cancers
Subjects:
real world
multiple myeloma
proteasome inhibitor
carfilzomib
relapsed/refractory
Online Access:https://www.mdpi.com/2072-6694/14/21/5311

Internet

https://www.mdpi.com/2072-6694/14/21/5311

Similar Items